Home > Boards > US Listed > Medical - Healthcare > Avalon GloboCare Corp (AVCO)

Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Quintessence Member Profile
 
Followed By 79
Posts 7,682
Boards Moderated 4
Alias Born 03/25/13
160x600 placeholder
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Cellular Therapy in the Asia Pacific Region” Session at the ... GlobeNewswire Inc. - 2/4/2020 9:00:10 AM
Avalon GloboCare to Present at Biotech Showcase™ 2020 GlobeNewswire Inc. - 1/6/2020 8:30:10 AM
Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines GlobeNewswire Inc. - 12/20/2019 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 4:37:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/31/2019 4:04:22 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2019 4:59:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2019 8:00:56 AM
Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants GlobeNewswire Inc. - 10/21/2019 8:00:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/26/2019 4:09:26 PM
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Ce... GlobeNewswire Inc. - 9/19/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2019 4:31:16 PM
Avalon GloboCare Announces $20 Million Credit Facility Provided by Company Chairman GlobeNewswire Inc. - 9/3/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/15/2019 9:02:47 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/15/2019 7:31:02 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 9:01:06 AM
Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production fo... GlobeNewswire Inc. - 7/22/2019 4:30:00 PM
Avalon GloboCare Provides Updates on its Lead Clinical Programs in CAR-T Therapy and Exosome-Based Regenerative Therapeutics GlobeNewswire Inc. - 7/15/2019 8:00:00 AM
Avalon GloboCare Appoints Dr. Yen-Michael Sheng Hsu, Founding Director of cGMP Cellular Therapy Facility at Weill Cornell Med... GlobeNewswire Inc. - 6/26/2019 8:30:00 AM
Avalon GloboCare Expected to Join the Russell 3000® Index PR Newswire (US) - 6/18/2019 8:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/17/2019 4:32:43 PM
Avalon GloboCare President and CEO David Jin, M.D., Ph.D. to Chair the "Research and Application of Stem Cell Exosomes" Sessi... PR Newswire (US) - 6/13/2019 8:00:00 AM
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product... PR Newswire (US) - 6/10/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 10:49:40 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 8:31:53 AM
Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy GlobeNewswire Inc. - 5/21/2019 9:00:00 AM
Quintessence   Thursday, 09/19/19 08:38:29 AM
Re: deri21 post# 173
Post # of 187 
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies

https://www.globenewswire.com/news-release/2019/09/19/1917937/0/en/Avalon-GloboCare-Announces-Initiation-of-First-in-Human-Clinical-Trial-of-its-CAR-T-Candidate-AVA-001-for-Treatment-of-B-Cell-Malignancies.html

“We have successfully evolved into an active clinical-stage company with a primary focus on immune effector cell therapy in the oncology domain. As our first-in-human clinical trial, the study of AVA-001 marks a significant milestone for Avalon. We are committed to delivering precise clinical execution and leadership in cell-based therapeutics with a strong pipeline of additional cellular immunotherapy candidates,” stated David Jin, M.D., Ph.D., President, Chief Executive Officer and Co-founder of Avalon.

JMHO. DYODD. "An investment in knowledge pays the best interest." - Benjamin Franklin
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist